Cao TT, Chen L, Zhen XF, Zhao GJ, Zhang HF, Hu Y. Dan Bai Xiao Formula combined with glucocorticoids and cyclophosphamide for pediatric lupus nephritis: A pilot prospective study. World J Clin Cases 2022; 10(31): 11391-11402 [PMID: 36387787 DOI: 10.12998/wjcc.v10.i31.11391]
Corresponding Author of This Article
Yan Hu, MD, PhD, Director, Doctor, Department of Traditional Chinese Medicine, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, No. 56 Nanlishi Road, Beijing 100045, China. huyan13370115073@163.com
Research Domain of This Article
Pediatrics
Article-Type of This Article
Clinical Trials Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 6, 2022; 10(31): 11391-11402 Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11391
Dan Bai Xiao Formula combined with glucocorticoids and cyclophosphamide for pediatric lupus nephritis: A pilot prospective study
Tong-Tong Cao, Li Chen, Xiao-Fang Zhen, Gao-Jie Zhao, Hui-Fang Zhang, Yan Hu
Tong-Tong Cao, Li Chen, Xiao-Fang Zhen, Gao-Jie Zhao, Hui-Fang Zhang, Yan Hu, Department of Traditional Chinese Medicine, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China
Author contributions: Cao TT drfted the manuscript; Hu Y revised the manuscript and supervised the study; Cao TT and Chen L performed the experiments; all authors agree to be accountable for all aspects of the work in ensuring integrity and accuracy.
Supported bythe Capital Health Research and Development of Special, No. CH2018-2-2092.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of Air Force Medical Center.
Conflict-of-interest statement: The authors decare that there are no known conflicts of interest associated with this publication and that there has been no significant financial support for this work that could have influenced its outcome.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Hu, MD, PhD, Director, Doctor, Department of Traditional Chinese Medicine, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, No. 56 Nanlishi Road, Beijing 100045, China. huyan13370115073@163.com
Received: May 31, 2022 Peer-review started: May 31, 2022 First decision: July 14, 2022 Revised: August 1, 2022 Accepted: September 21, 2022 Article in press: September 21, 2022 Published online: November 6, 2022 Processing time: 148 Days and 13.8 Hours
Core Tip
Core Tip: Lupus nephritis (LN) is the most common and serious complication of systemic lupus erythematosus. Glucocorticoids (GCs) and immunosuppressants were considered routine treatments for patients with LN. However, there is a widespread consensus regarding the toxicity of immunosuppressive agents and the necessity of preventing children from taking these medications over an extended period. Accordingly, there is an increasing need for holistic and optimal therapy that results in a higher rate of remission and fewer side effects. Our study suggests that Dan Bai Xiao Formula (DBXF) treatment is effective and safe as a supplementary therapy for LN; moreover, this treatment is superior to routine GC and cyclophosphamide therapies. DBXF containing combination treatment may lead to faster proteinuria and hematuria resolution, smoother GC reduction, fewer methylprednisolone pulses, and fewer adverse events.
